TriangleNCT02761187 · OUTCOME
Duration of Treatment for Participants With and Without Stem Cell Transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- Baseline up to 5 years
What was measured
Data was analyzed for participants with and without stem cell transplant for all enrolled population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data.
Analysis population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. Overall number analyzed are the number of participants with data available for analyses. The data is reported as per the known line of therapies.
Groups in this outcome
1st Line of Therapy
The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
2nd Line of Therapy
The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
3rd Line of Therapy
The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
4th Line of Therapy
The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
>4th Line of Therapy
The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
| Group | Source count |
|---|---|
| 1st Line of Therapy | 1597 |
| 2nd Line of Therapy | 575 |
| 3rd Line of Therapy | 390 |
| 4th Line of Therapy | 227 |
| >4th Line of Therapy | 77 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 1st Line of Therapy | 4.5 | Not reported | 0 | 45 | Not reported |
| 2nd Line of Therapy | 6.4 | Not reported | 0 | 57 | Not reported |
| 3rd Line of Therapy | 9.2 | Not reported | 0 | 80 | Not reported |
| 4th Line of Therapy | 11.5 | Not reported | 0 | 68 | Not reported |
| >4th Line of Therapy | 11.5 | Not reported | 0 | 52 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 45
- value
- 4.5
- group Id
- OG001
- lower Limit
- 0
- upper Limit
- 57
- value
- 6.4
- group Id
- OG002
- lower Limit
- 0
- upper Limit
- 80
- value
- 9.2
- group Id
- OG003
- lower Limit
- 0
- upper Limit
- 68
- value
- 11.5
- group Id
- OG004
- lower Limit
- 0
- upper Limit
- 52
- value
- 11.5
- denoms
- counts
- group Id
- OG000
- value
- 1597
- group Id
- OG001
- value
- 575
- group Id
- OG002
- value
- 390
- group Id
- OG003
- value
- 227
- group Id
- OG004
- value
- 77
- units
- Participants
- description
- Data was analyzed for participants with and without stem cell transplant for all enrolled population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data.
- dispersion Type
- Full Range
- groups
- description
- The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG000
- title
- 1st Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG001
- title
- 2nd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG002
- title
- 3rd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG003
- title
- 4th Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG004
- title
- >4th Line of Therapy
- param Type
- MEDIAN
- population Description
- All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. Overall number analyzed are the number of participants with data available for analyses. The data is reported as per the known line of therapies.
- reporting Status
- POSTED
- time Frame
- Baseline up to 5 years
- title
- Duration of Treatment for Participants With and Without Stem Cell Transplant
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice